A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection

Inclusion Criteria:

• Male or female (of nonchildbearing potential, practicing total abstinence, sexuallyactive with female partners only, or using allowed contraceptive methods) at least 18years of age at time of screening.
• Screening laboratory result indicating HCV GT3 infection.
• Chronic HCV infection, defined as one of the following:
• Positive for anti-HCV antibody (Ab) or HCV RNA at least 6 months beforescreening; or
• A liver biopsy consistent with chronic HCV infection; or
• Abnormal alanine aminotransferase (ALT) levels for at least 6 months beforescreening.
• Hepatitis C virus treatment-naïve (i.e., participant had never received any anti-HCVtreatment).
• Documented as noncirrhotic.

Exclusion Criteria:

• Female who was pregnant, planning to become pregnant during the study, orbreastfeeding; or male whose partner was pregnant or planning to become pregnantduring the study.
• Recent (within 6 months prior to study drug administration) history of drug or alcoholabuse that could have precluded adherence to the protocol in the opinion of theinvestigator.
• Positive test result at screening for hepatitis B surface antigen (HBsAg) oranti-human immunodeficiency virus Ab (HIV Ab).
• Hepatitis C virus genotyping performed during screening indicated co-infection withmore than one HCV genotype.
• Any cause of liver disease other than chronic HCV infection.
• Consideration by the investigator, for any reason, that the participant was anunsuitable candidate to receive ABT-493/ABT-530, SOF, or DCV.
• History of severe, life-threatening, or other significant sensitivity to anyexcipients of the study drug.
• Previous use of any anti-HCV treatment.